Emmanuelle de Raucourt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emmanuelle de Raucourt has a total of 305 co-authors. Here are the top co-authors by number of shared publications:
- Pierre-Emmanuel Rautou
Université Paris-Cité, Inserm, Centre de recherche sur l’inflammation, UMR 1149, Paris, France
7 shared publications - Dominique Valla
Université Paris Cité and Inserm, Paris, France
6 shared publications A. M. Fischer
Faculté de Médecine, Université Paris‐Descartes, Paris
5 shared publicationsLarbi Boudaoud
Service d'Hématologie-Biologique, Hôpital Beaujon, HUPNVS, AP-HP Clichy, France
4 shared publications- Nadine Ajzenberg
Bichat-Claude Bernard Hospital, University Paris Diderot
4 shared publications Aurélie Plessier
DHU Unity, Pôle des Maladies de l'Appareil Digestif, Service d'Hépatologie, Centre de Référence des Maladies Vasculaires du Foie, Hôpital Beaujon, AP-HP, Clichy, France
3 shared publications
Latest Publications
- Open Access
- 26 August 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (12) , 101563
Platelet protease nexin-1 limits fibrinolysis in patients with cirrhosis
- 26 August 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (12) , 101563
Open AccessPlatelet protease nexin-1 limits fibrinolysis in patients with cirrhosis
- 29 July 2025
- Published by Wiley in Haemophilia
- Vol. 31 (6) , 1328-1331
Analytical Performance of an Automated Method for Measuring von Willebrand Factor Activity in Clinical Samples on the New Analyser sthemO 301
- 29 July 2025
- Published by Wiley in Haemophilia
- Vol. 31 (6) , 1328-1331
Analytical Performance of an Automated Method for Measuring von Willebrand Factor Activity in Clinical Samples on the New Analyser sthemO 301
- Open Access
- 30 May 2023
- Published by Wiley in Haemophilia
- Vol. 29 (4) , 1113-1120
A focus on dominant negative variants in a series of 170 heterozygous FXI‐deficient patients
IntroductionDominant-negative effects have been described for 10 F11 variants in the literature. AimThe current study aimed at identifying putative dominant-negative F11 variants. Material and methodsThis research consisted in a retrospective analysis of routine laboratory data. ResultsIn a series of 170 patients with moderate/mild factor XI (FXI) deficiencies, we identified heterozygous carriers of previously reported dominant-negative variants (p.Ser243Phe, p.Cys416Tyr, and p.Gly418Val) with FXI activities inconsistent with a dominant-negative effect. Our findings also do not support a dominant-negative effect of p.Gly418Ala. We also identified a set of patients carrying heterozygous variants, among which five out of 11 are novel, with FXI activities suggesting a dominant-negative effect (p.His53Tyr, p.Cys110Gly, p.Cys140Tyr, p.Glu245Lys, p.Trp246Cys, p.Glu315Lys, p.Ile421Thr, p.Trp425Cys, p.Glu565Lys, p.Thr593Met, and p.Trp617Ter). However, for all but two of these variants, individuals with close to half normal FXI coagulant activity (FXI:C) were identified, indicating an inconstant dominant effect. ConclusionOur data show that for some F11 variants recognized has having dominant-negative effects, such effects actually do not occur in many individuals. The present data suggest that for these patients, the intracellular quality control mechanisms eliminate the variant monomeric polypeptide before homodimer assembly, thereby allowing only the wild-type homodimer to assemble and resulting in half normal activities. In contrast, in patients with markedly decreased activities, some mutant polypeptides might escape this first quality control. In turn, assembly of heterodimeric molecules as well as mutant homodimers would result in activities closer to 1:4 of FXI:C normal range.
- 30 May 2023
- Published by Wiley in Haemophilia
- Vol. 29 (4) , 1113-1120
Open AccessA focus on dominant negative variants in a series of 170 heterozygous FXI‐deficient patients
IntroductionDominant-negative effects have been described for 10 F11 variants in the literature. AimThe current study aimed at identifying putative dominant-negative F11 variants. Material and methodsThis research consisted in a retrospective analysis of routine laboratory data. ResultsIn a series of 170 patients with moderate/mild factor XI (FXI) deficiencies, we identified heterozygous carriers of previously reported dominant-negative variants (p.Ser243Phe, p.Cys416Tyr, and p.Gly418Val) with FXI activities inconsistent with a dominant-negative effect. Our findings also do not support a dominant-negative effect of p.Gly418Ala. We also identified a set of patients carrying heterozygous variants, among which five out of 11 are novel, with FXI activities suggesting a dominant-negative effect (p.His53Tyr, p.Cys110Gly, p.Cys140Tyr, p.Glu245Lys, p.Trp246Cys, p.Glu315Lys, p.Ile421Thr, p.Trp425Cys, p.Glu565Lys, p.Thr593Met, and p.Trp617Ter). However, for all but two of these variants, individuals with close to half normal FXI coagulant activity (FXI:C) were identified, indicating an inconstant dominant effect. ConclusionOur data show that for some F11 variants recognized has having dominant-negative effects, such effects actually do not occur in many individuals. The present data suggest that for these patients, the intracellular quality control mechanisms eliminate the variant monomeric polypeptide before homodimer assembly, thereby allowing only the wild-type homodimer to assemble and resulting in half normal activities. In contrast, in patients with markedly decreased activities, some mutant polypeptides might escape this first quality control. In turn, assembly of heterodimeric molecules as well as mutant homodimers would result in activities closer to 1:4 of FXI:C normal range.
- Open Access
- 21 September 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (12) , 2786-2796
Predicting bleeding after liver biopsy using comprehensive clinical and laboratory investigations: A prospective analysis of 302 procedures
- 21 September 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (12) , 2786-2796
Open AccessPredicting bleeding after liver biopsy using comprehensive clinical and laboratory investigations: A prospective analysis of 302 procedures
- Open Access
- 1 March 2021
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. ume 12, 133-138
The Hemarthrosis-Simulating Knee Model: A Useful Tool for Individualized Education in Patients with Hemophilia (GEFACET Study)
Background: Hemophilic arthropathy is a major complication in patients with severe hemophilia. A plastic knee model has been developed for the therapeutic education of patients to promote improved care management and self-treatment skills. The objective of this study was to evaluate the impact of this hemarthrosis-simulating artificial knee (HSAK) on patients’ knowledge of their disease and its treatment. Methods: In this observational study, the impact of HSAK was assessed during individualized education in patients with severe/moderately severe hemophilia A or B at seven hemophilia treatment centers in France. Participants provided written informed consent and completed questionnaires to assess knowledge of their disease (score range: 0– 7) and knowledge of their treatment (score range: 0– 4). Questionnaires were completed before, immediately after and 6 months after HSAK use. The scores obtained before and after the use of the HSAK were compared. Results: The participants comprised 32 children, 29 teenagers, and 31 adults. The mean (SD) disease knowledge score increased significantly in all age groups of patients from 4.5 (2.0) to 5.9 (1.5; p< 0.001) immediately after the training and remained unchanged at 6 months. Mean (SD) treatment knowledge scores were unchanged, but Wilcoxon signed rank testing showed a significant increase after the training course that was maintained at 6 months in children and teenagers. Conclusion: These findings suggest that an individualized training course can enhance the understanding of hemophilia in patients of all ages, especially in children and teenagers, and that the HSAK may assist in improving patients’ management of their disease.
- 1 March 2021
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. ume 12, 133-138
Open AccessThe Hemarthrosis-Simulating Knee Model: A Useful Tool for Individualized Education in Patients with Hemophilia (GEFACET Study)
Background: Hemophilic arthropathy is a major complication in patients with severe hemophilia. A plastic knee model has been developed for the therapeutic education of patients to promote improved care management and self-treatment skills. The objective of this study was to evaluate the impact of this hemarthrosis-simulating artificial knee (HSAK) on patients’ knowledge of their disease and its treatment. Methods: In this observational study, the impact of HSAK was assessed during individualized education in patients with severe/moderately severe hemophilia A or B at seven hemophilia treatment centers in France. Participants provided written informed consent and completed questionnaires to assess knowledge of their disease (score range: 0– 7) and knowledge of their treatment (score range: 0– 4). Questionnaires were completed before, immediately after and 6 months after HSAK use. The scores obtained before and after the use of the HSAK were compared. Results: The participants comprised 32 children, 29 teenagers, and 31 adults. The mean (SD) disease knowledge score increased significantly in all age groups of patients from 4.5 (2.0) to 5.9 (1.5; p< 0.001) immediately after the training and remained unchanged at 6 months. Mean (SD) treatment knowledge scores were unchanged, but Wilcoxon signed rank testing showed a significant increase after the training course that was maintained at 6 months in children and teenagers. Conclusion: These findings suggest that an individualized training course can enhance the understanding of hemophilia in patients of all ages, especially in children and teenagers, and that the HSAK may assist in improving patients’ management of their disease.
- 6 February 2021
- Published by Wiley in Haemophilia
- Vol. 27 (2) , 270-276
Efficacy and safety of a recombinant Von Willebrand Factor treatment in patients with inherited Von Willebrand Disease requiring surgical procedures
Introduction: Von Willebrand Disease is a common inherited haemorrhagic disorder due to a deficiency of Von Willebrand Factor (VWF). In case of surgical procedures in patients who are not responsive or have contraindications to desmopressin, replacement therapy with VWF concentrates is indicated. Until recently, only plasma‐derived VWF concentrates were available. A new recombinant VWF (rVWF) concentrate that contains no Factor VIII (FVIII) but a high amount of high molecular weight VWF multimers has been available in France since 2018.Aim: Describe real‐world experience of using rVWF in surgical procedures.Methods: Sixty‐three surgeries for 55 patients were retrospectively analysed in 7 French haemostasis centres.Results: During minor surgeries, the median (range) number of infusions was 1 (1–8) with a preoperative loading dose of 35 (19–56) rVWF IU/kg and a total median dose of 37.5 IU (12–288). During major surgeries, the median (range) number of infusions was only 3 (1–14) with a median preoperative loading dose of 36 IU (12–51) rVWF IU/kg, and a total median dose of 108 IU (22–340) rVWF IU/kg. The overall clinical efficacy was qualified as excellent/good in 61 of the procedures (97%), moderate in 1 (1.5%) and poor in 1 (1.5%). There was no accumulation of VWF or FVIII during postoperative monitoring. No thromboembolic events, anti‐VWF antibodies or adverse events were reported.Conclusion: This French ‘real‐world’ experience shows that a few infusions and low doses of rVWF provided effective prevention of bleeding in major and minor surgeries in inherited VWD, with no clinically significant safety concerns.
- 6 February 2021
- Published by Wiley in Haemophilia
- Vol. 27 (2) , 270-276
Efficacy and safety of a recombinant Von Willebrand Factor treatment in patients with inherited Von Willebrand Disease requiring surgical procedures
Introduction: Von Willebrand Disease is a common inherited haemorrhagic disorder due to a deficiency of Von Willebrand Factor (VWF). In case of surgical procedures in patients who are not responsive or have contraindications to desmopressin, replacement therapy with VWF concentrates is indicated. Until recently, only plasma‐derived VWF concentrates were available. A new recombinant VWF (rVWF) concentrate that contains no Factor VIII (FVIII) but a high amount of high molecular weight VWF multimers has been available in France since 2018.Aim: Describe real‐world experience of using rVWF in surgical procedures.Methods: Sixty‐three surgeries for 55 patients were retrospectively analysed in 7 French haemostasis centres.Results: During minor surgeries, the median (range) number of infusions was 1 (1–8) with a preoperative loading dose of 35 (19–56) rVWF IU/kg and a total median dose of 37.5 IU (12–288). During major surgeries, the median (range) number of infusions was only 3 (1–14) with a median preoperative loading dose of 36 IU (12–51) rVWF IU/kg, and a total median dose of 108 IU (22–340) rVWF IU/kg. The overall clinical efficacy was qualified as excellent/good in 61 of the procedures (97%), moderate in 1 (1.5%) and poor in 1 (1.5%). There was no accumulation of VWF or FVIII during postoperative monitoring. No thromboembolic events, anti‐VWF antibodies or adverse events were reported.Conclusion: This French ‘real‐world’ experience shows that a few infusions and low doses of rVWF provided effective prevention of bleeding in major and minor surgeries in inherited VWD, with no clinically significant safety concerns.
- 22 December 2019
- Published by Wiley in Haemophilia
- Vol. 26 (2) , E44-E48
Assessment of primary haemostasis with a new recombinant von Willebrand factor in patients with von Willebrand disease
- 22 December 2019
- Published by Wiley in Haemophilia
- Vol. 26 (2) , E44-E48
Assessment of primary haemostasis with a new recombinant von Willebrand factor in patients with von Willebrand disease
- 1 September 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 67 (3) , 501-507
Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study
- 1 September 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 67 (3) , 501-507
Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study
- 1 July 2017
- Published by Elsevier in Thrombosis Research
- Vol. 155, 28-30
Thrombin generation in patients with non-cirrhotic vascular liver diseases treated or not treated with vitamin K antagonist
- 1 July 2017
- Published by Elsevier in Thrombosis Research
- Vol. 155, 28-30
Thrombin generation in patients with non-cirrhotic vascular liver diseases treated or not treated with vitamin K antagonist
- 1 July 2017
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 127 (1) , 111-120
Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants
Background: The use of prothrombin complex concentrates and the role of plasma concentration of anticoagulants in the management of bleeding in patients treated with direct oral anticoagulants are still debated. Our aim was to describe management strategies and outcomes of severe bleeding events in patients treated with direct oral anticoagulants. Methods: We performed a prospective cohort study of 732 patients treated with dabigatran, rivaroxaban, or apixaban hospitalized for severe bleeding, included prospectively in the registry from June 2013 to November 2015. Results: Bleeding was gastrointestinal or intracranial in 37% (212 of 732) and 24% (141 of 732) of the cases, respectively. Creatinine clearance was lower than 60 ml/min in 61% (449 of 732) of the cases. The plasma concentration of direct oral anticoagulants was determined in 62% (452 of 732) of the cases and was lower than 50 ng/ml or higher than 400 ng/ml in 9.2% (41 of 452) and in 6.6% (30 of 452) of the cases, respectively. Activated or nonactivated prothrombin complex concentrates were administered in 38% of the cases (281 of 732). Mortality by day 30 was 14% (95% CI, 11 to 16). Conclusions: Management of severe bleeding in patients treated with direct oral anticoagulants appears to be complex. The use of prothrombin complex concentrates differs depending on bleeding sites and direct oral anticoagulant plasma concentrations. Mortality differs according to bleeding sites and was similar to previous estimates.
- 1 July 2017
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 127 (1) , 111-120
Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants
Background: The use of prothrombin complex concentrates and the role of plasma concentration of anticoagulants in the management of bleeding in patients treated with direct oral anticoagulants are still debated. Our aim was to describe management strategies and outcomes of severe bleeding events in patients treated with direct oral anticoagulants. Methods: We performed a prospective cohort study of 732 patients treated with dabigatran, rivaroxaban, or apixaban hospitalized for severe bleeding, included prospectively in the registry from June 2013 to November 2015. Results: Bleeding was gastrointestinal or intracranial in 37% (212 of 732) and 24% (141 of 732) of the cases, respectively. Creatinine clearance was lower than 60 ml/min in 61% (449 of 732) of the cases. The plasma concentration of direct oral anticoagulants was determined in 62% (452 of 732) of the cases and was lower than 50 ng/ml or higher than 400 ng/ml in 9.2% (41 of 452) and in 6.6% (30 of 452) of the cases, respectively. Activated or nonactivated prothrombin complex concentrates were administered in 38% of the cases (281 of 732). Mortality by day 30 was 14% (95% CI, 11 to 16). Conclusions: Management of severe bleeding in patients treated with direct oral anticoagulants appears to be complex. The use of prothrombin complex concentrates differs depending on bleeding sites and direct oral anticoagulant plasma concentrations. Mortality differs according to bleeding sites and was similar to previous estimates.